[
  {
    "timestamp": "2025-12-28T09:43:22.906511Z",
    "step": "medication_analysis",
    "system_prompt": "You are a clinical pharmacist producing structured medication analysis. Return ONLY valid JSON.\n\nGrok output quality requirements: be exhaustive, avoid placeholders, and provide complete, clinically useful detail. If evidence is limited, label it as limited evidence but still provide guidance.",
    "user_prompt": "\nAnalyze the medication below and return a comprehensive structured report.\n\nMedication: paracetamol\nIndication: N/A\nOther medications: None\nWeb research context:\nNone\n\nReturn JSON matching this schema:\n{'$defs': {'_InteractionModel': {'properties': {'interaction_type': {'title': 'Interaction Type', 'type': 'string'}, 'interacting_agent': {'title': 'Interacting Agent', 'type': 'string'}, 'severity': {'title': 'Severity', 'type': 'string'}, 'mechanism': {'title': 'Mechanism', 'type': 'string'}, 'clinical_effect': {'title': 'Clinical Effect', 'type': 'string'}, 'management': {'title': 'Management', 'type': 'string'}, 'time_separation': {'anyOf': [{'type': 'string'}, {'type': 'null'}], 'default': None, 'title': 'Time Separation'}, 'evidence_level': {'default': 'moderate', 'title': 'Evidence Level', 'type': 'string'}}, 'required': ['interaction_type', 'interacting_agent', 'severity', 'mechanism', 'clinical_effect', 'management'], 'title': '_InteractionModel', 'type': 'object'}}, 'properties': {'medication_name': {'title': 'Medication Name', 'type': 'string'}, 'drug_class': {'title': 'Drug Class', 'type': 'string'}, 'mechanism_of_action': {'title': 'Mechanism Of Action', 'type': 'string'}, 'absorption': {'title': 'Absorption', 'type': 'string'}, 'metabolism': {'title': 'Metabolism', 'type': 'string'}, 'elimination': {'title': 'Elimination', 'type': 'string'}, 'half_life': {'title': 'Half Life', 'type': 'string'}, 'approved_indications': {'items': {'type': 'string'}, 'title': 'Approved Indications', 'type': 'array'}, 'off_label_uses': {'items': {'type': 'string'}, 'title': 'Off Label Uses', 'type': 'array'}, 'standard_dosing': {'default': '', 'title': 'Standard Dosing', 'type': 'string'}, 'dose_adjustments': {'additionalProperties': {'type': 'string'}, 'title': 'Dose Adjustments', 'type': 'object'}, 'common_adverse_effects': {'items': {'type': 'string'}, 'title': 'Common Adverse Effects', 'type': 'array'}, 'serious_adverse_effects': {'items': {'type': 'string'}, 'title': 'Serious Adverse Effects', 'type': 'array'}, 'contraindications': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'Contraindications', 'type': 'array'}, 'black_box_warnings': {'items': {'type': 'string'}, 'title': 'Black Box Warnings', 'type': 'array'}, 'drug_interactions': {'items': {'$ref': '#/$defs/_InteractionModel'}, 'title': 'Drug Interactions', 'type': 'array'}, 'food_interactions': {'items': {'$ref': '#/$defs/_InteractionModel'}, 'title': 'Food Interactions', 'type': 'array'}, 'environmental_considerations': {'items': {'type': 'string'}, 'title': 'Environmental Considerations', 'type': 'array'}, 'evidence_based_recommendations': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'Evidence Based Recommendations', 'type': 'array'}, 'what_not_to_do': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'What Not To Do', 'type': 'array'}, 'debunked_claims': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'Debunked Claims', 'type': 'array'}, 'monitoring_requirements': {'items': {'type': 'string'}, 'title': 'Monitoring Requirements', 'type': 'array'}, 'warning_signs': {'items': {'additionalProperties': {'type': 'string'}, 'type': 'object'}, 'title': 'Warning Signs', 'type': 'array'}, 'evidence_quality': {'default': 'moderate', 'title': 'Evidence Quality', 'type': 'string'}, 'analysis_confidence': {'default': 0.75, 'title': 'Analysis Confidence', 'type': 'number'}}, 'required': ['medication_name', 'drug_class', 'mechanism_of_action', 'absorption', 'metabolism', 'elimination', 'half_life'], 'title': '_MedicationOutputModel', 'type': 'object'}\n\n\nRecommendations guidance:\n- \"evidence_based_recommendations\": evidence-based WHAT TO DO actions with rationale, evidence_level,\n  implementation, expected_outcome, and monitoring when possible.\n- \"what_not_to_do\": evidence-based WHAT NOT TO DO actions with risks and safer alternatives.\n- \"debunked_claims\": false or misleading public beliefs about the medicine. A debunked claim must be:\n  1) a specific, commonly repeated statement,\n  2) contradicted by labeling/guidelines/trials/large reviews,\n  3) distinct from behavior advice (avoid overlap with WHAT NOT TO DO).\n  Provide claim, reason_debunked, evidence, why_harmful, and debunked_by when possible.\nRequirements:\n- Do not leave \"intervention\" or \"action\" blank. Use a short imperative sentence.\n- Avoid \"N/A\". If unknown, write \"not established\" with a brief rationale.\n\n\nGrok-specific requirements:\n- Do not omit any section in the schema.\n- Provide \u22653 items for list fields when applicable (interactions, adverse effects, recommendations).\n- Ensure contraindications and warning signs are populated with realistic clinical content.\n- Use evidence qualifiers (e.g., strong/moderate/limited) instead of leaving empty.\n\n\nDo NOT use 'N/A'. If unknown, use 'not established' and provide rationale. For narrative fields, write at least 2-3 sentences. Include numeric values (doses, timeframes, ranges) whenever possible.",
    "response": "```json\n{\n  \"medication_name\": \"Paracetamol\",\n  \"drug_class\": \"Non-opioid analgesic and antipyretic\",\n  \"mechanism_of_action\": \"Paracetamol selectively inhibits cyclooxygenase (COX-2) more than COX-1 in the central nervous system, reducing prostaglandin synthesis and thereby mediating analgesic and antipyretic effects. It exhibits weak peripheral anti-inflammatory activity compared to NSAIDs. The exact central mechanism may involve additional pathways such as serotoninergic and cannabinoid systems.\",\n  \"absorption\": \"Paracetamol is rapidly and nearly completely absorbed from the small intestine after oral administration, with bioavailability of 70-90%. Peak plasma concentrations are achieved within 0.5-2 hours post-dose. Food, particularly high-fat meals, may delay absorption by 0.5-1 hour without significantly altering extent.\",\n  \"metabolism\": \"Primarily hepatic metabolism occurs via phase II conjugation: 50-60% to paracetamol-glucuronide, 25-35% to paracetamol-sulfate, and 5-10% via CYP2E1 (minor contributions from CYP1A2 and CYP3A4) to the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is detoxified by glutathione under normal conditions. In overdose, glutathione depletion leads to NAPQI accumulation and hepatotoxicity.\",\n  \"elimination\": \"Elimination is predominantly renal, with 90-100% of dose excreted as metabolites in urine within 24 hours; less than 5% is excreted unchanged. Total body clearance is 350-500 mL/min in adults. Half-life prolongation occurs in renal impairment due to metabolite accumulation.\",\n  \"half_life\": \"1.5-3 hours in healthy adults; 3-8 hours in hepatic impairment; up to 10-15 hours in neonates or severe overdose.\",\n  \"approved_indications\": [\n    \"Mild to moderate acute pain\",\n    \"Fever reduction\",\n    \"Symptomatic relief of common cold and influenza\"\n  ],\n  \"off_label_uses\": [\n    \"Chronic osteoarthritis pain (adjunct to NSAIDs)\",\n    \"Headache prophylaxis in limited cases\",\n    \"Postoperative analgesia adjunct (moderate evidence)\"\n  ],\n  \"standard_dosing\": \"Adults and adolescents >12 years: 500-1000 mg orally every 4-6 hours as needed, maximum 4000 mg/day. Children 1 month-12 years: 10-15 mg/kg/dose every 4-6 hours, maximum 75 mg/kg/day or 4000 mg/day. IV dosing: 1000 mg every 6 hours, max 4000 mg/day.\",\n  \"dose_adjustments\": {\n    \"Hepatic impairment (mild)\": \"Maximum 3000 mg/day; monitor LFTs.\",\n    \"Hepatic impairment (moderate-severe)\": \"Maximum 2000 mg/day or avoid; consult hepatologist.\",\n    \"Renal impairment (CrCl 10-50 mL/min)\": \"Maximum 3000 mg/day.\",\n    \"Renal impairment (CrCl <10 mL/min or dialysis)\": \"Maximum 2000 mg/day; dose after dialysis.\",\n    \"Elderly (>65 years)\": \"Start at 500 mg/dose; maximum 3000 mg/day due to reduced clearance.\",\n    \"Chronic alcoholics\": \"Maximum 2000 mg/day; increased hepatotoxicity risk.\"\n  },\n  \"common_adverse_effects\": [\n    \"Nausea (3-5%)\",\n    \"Vomiting (1-3%)\",\n    \"Rash (1-2%)\",\n    \"Pruritus\",\n    \"Dizziness\"\n  ],\n  \"serious_adverse_effects\": [\n    \"Acute hepatotoxicity (overdose >150 mg/kg)\",\n    \"Anaphylaxis/hypersensitivity\",\n    \"Stevens-Johnson syndrome/toxic epidermal necrolysis (rare)\",\n    \"Metabolic acidosis (high-dose IV)\"\n  ],\n  \"contraindications\": [\n    {\n      \"Hypersensitivity to paracetamol or excipients\": \"Risk of anaphylaxis or severe skin reactions.\"\n    },\n    {\n      \"Severe active hepatic disease (e.g., Child-Pugh C)\": \"Exacerbates hepatotoxicity due to impaired detoxification.\"\n    },\n    {\n      \"Severe renal impairment (CrCl <10 mL/min without dialysis)\": \"Risk of metabolite accumulation; not established safe.\"\n    }\n  ],\n  \"black_box_warnings\": [\n    \"Severe liver injury may occur with therapeutic doses (>4000 mg/day) or overdose; acute liver failure can lead to transplantation or death.\",\n    \"Do not exceed recommended dose; multiple products may contain paracetamol leading to inadvertent overdose.\"\n  ],\n  \"drug_interactions\": [\n    {\n      \"interaction_type\": \"Pharmacodynamic\",\n      \"interacting_agent\": \"Warfarin\",\n      \"severity\": \"Moderate\",\n      \"mechanism\": \"Paracetamol may inhibit warfarin metabolism (CYP2C9) or displace from protein binding.\",\n      \"clinical_effect\": \"Elevated INR, increased bleeding risk.\",\n      \"management\": \"Monitor INR frequently (weekly initially); consider alternative analgesic if chronic use.\",\n      \"time_separation\": null,\n      \"evidence_level\": \"moderate\"\n    },\n    {\n      \"interaction_type\": \"Pharmacokinetic\",\n      \"interacting_agent\": \"Probenecid\",\n      \"severity\": \"Moderate\",\n      \"mechanism\": \"Probenecid inhibits glucuronidation and renal excretion of paracetamol.\",\n      \"clinical_effect\": \"Increased paracetamol levels and half-life.\",\n      \"management\": \"Reduce paracetamol dose by 50%; monitor for toxicity.\",\n      \"time_separation\": null,\n      \"evidence_level\": \"limited\"\n    },\n    {\n      \"interaction_type\": \"Pharmacodynamic\",\n      \"interacting_agent\": \"Alcohol (chronic use)\",\n      \"severity\": \"Major\",\n      \"mechanism\": \"Induction of CYP2E1 increases NAPQI production; glutathione depletion.\",\n      \"clinical_effect\": \"Enhanced hepatotoxicity risk even at therapeutic doses.\",\n      \"management\": \"Avoid concurrent use or limit paracetamol to 2 g/day; counsel on abstinence.\",\n      \"time_separation\": null,\n      \"evidence_level\": \"strong\"\n    },\n    {\n      \"interaction_type\": \"Pharmacokinetic\",\n      \"interacting_agent\": \"Isoniazid\",\n      \"severity\": \"Moderate\",\n      \"mechanism\": \"Induction of CYP2E1 increases NAPQI formation.\",\n      \"clinical_effect\": \"Potential hepatotoxicity.\",\n      \"management\": \"Monitor LFTs; use lowest effective dose.\",\n      \"time_separation\": null,\n      \"evidence_level\": \"moderate\"\n    }\n  ],\n  \"food_interactions\": [\n    {\n      \"interaction_type\": \"Pharmacokinetic\",\n      \"interacting_agent\": \"High-fat meals\",\n      \"severity\": \"Mild\",\n      \"mechanism\": \"Delayed gastric emptying reduces absorption rate.\",\n      \"clinical_effect\": \"Delayed time to peak concentration (Tmax increased by 0.5-1 hour); no change in AUC.\",\n      \"management\": \"No dose adjustment; administer without regard to meals.\",\n      \"time_separation\": null,\n      \"evidence_level\": \"moderate\"\n    },\n    {\n      \"interaction_type\": \"Pharmacodynamic\",\n      \"interacting_agent\": \"Alcohol (acute ingestion)\",\n      \"severity\": \"Moderate\",\n      \"mechanism\": \"Acute alcohol inhibits CYP2E1, but chronic induces it; variable glutathione effects.\",\n      \"clinical_effect\": \"Unpredictable hepatotoxicity risk.\",\n      \"management\": \"Separate by >4 hours if possible; avoid in chronic users.\",\n      \"time_separation\": \"4 hours\",\n      \"evidence_level\": \"limited\"\n    }\n  ],\n  \"environmental_considerations\": [\n    \"Store below 25\u00b0C (77\u00b0F), protected from light and moisture to maintain stability.\",\n    \"Avoid freezing IV formulations; discard if discolored or particulate.\",\n    \"Proper disposal of unused medication via take-back programs to prevent aquatic contamination by metabolites.\"\n  ],\n  \"evidence_based_recommendations\": [\n    {\n      \"action\": \"Limit daily dose to 4000 mg in adults without risk factors.\",\n      \"rationale\": \"Reduces risk of hepatotoxicity based on pharmacokinetic data and overdose epidemiology.\",\n      \"evidence_level\": \"strong\",\n      \"implementation\": \"Educate on total intake from all sources (e.g., combination products).\",\n      \"expected_outcome\": \"Safe analgesia with <0.01% hepatotoxicity incidence.\",\n      \"monitoring\": \"Query for symptoms if >3 g/day.\"\n    },\n    {\n      \"action\": \"Administer antidote N-acetylcysteine (NAC) within 8 hours of overdose.\",\n      \"rationale\": \"Replenishes glutathione to detoxify NAPQI; Rumack-Matthew nomogram guides need.\",\n      \"evidence_level\": \"strong\",\n      \"implementation\": \"IV NAC 150 mg/kg over 1 hour, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours.\",\n      \"expected_outcome\": \"Hepatotoxicity prevention if initiated early (>90% efficacy).\",\n      \"monitoring\": \"Serum paracetamol levels at 4 hours post-ingestion; LFTs.\"\n    },\n    {\n      \"action\": \"Screen for chronic alcohol use before chronic therapy.\",\n      \"rationale\": \"CYP2E1 induction increases NAPQI; limited evidence supports dose cap.\",\n      \"evidence_level\": \"moderate\",\n      \"implementation\": \"AUDIT-C questionnaire; cap at 2000 mg/day if positive.\",\n      \"expected_outcome\": \"Minimized liver injury risk.\",\n      \"monitoring\": \"Baseline and monthly LFTs.\"\n    }\n  ],\n  \"what_not_to_do\": [\n    {\n      \"action\": \"Do not combine multiple paracetamol-containing products without dose calculation.\",\n      \"risks\": \"Inadvertent overdose leading to acute liver failure (40% of US cases).\",\n      \"safer_alternatives\": \"Use single-ingredient products; opt for ibuprofen if appropriate.\"\n    },\n    {\n      \"action\": \"Do not use long-term (>14 days) without LFT monitoring.\",\n      \"risks\": \"Cumulative hepatotoxicity, especially >2 g/day.\",\n      \"safer_alternatives\": \"Alternate with NSAIDs or opioid adjuncts under supervision.\"\n    },\n    {\n      \"action\": \"Do not administer to patients with G6PD deficiency routinely.\",\n      \"risks\": \"Limited evidence of hemolytic anemia (case reports).\",\n      \"safer_alternatives\": \"Aspirin or non-pharmacologic pain relief.\"\n    }\n  ],\n  \"debunked_claims\": [\n    {\n      \"claim\": \"Paracetamol is completely safe with no risk of liver damage at any dose.\",\n      \"reason_debunked\": \"Therapeutic misadventure causes 50% of acute liver failure cases.\",\n      \"evidence\": \"FDA labeling, Rumack nomogram trials, AASLD guidelines.\",\n      \"why_harmful\": \"Encourages overdose, delaying care.\",\n      \"debunked_by\": \"NEJM reviews (2000s overdose data)\"\n    },\n    {\n      \"claim\": \"Paracetamol cures the common cold or flu.\",\n      \"reason_debunked\": \"Symptomatic relief only; no antiviral activity.\",\n      \"evidence\": \"Cochrane reviews show no reduction in duration.\",\n      \"why_harmful\": \"Delays seeking care for complications.\",\n      \"debunked_by\": \"RCTs (e.g., 2013 meta-analysis)\"\n    },\n    {\n      \"claim\": \"Daily paracetamol prevents hangovers.\",\n      \"reason_debunked\": \"No prophylactic efficacy; increases hepatotoxicity with alcohol.\",\n      \"evidence\": \"Small trials show no benefit over placebo.\",\n      \"why_harmful\": \"Promotes unsafe alcohol-paracetamol pairing.\",\n      \"debunked_by\": \"Pharmacoepidemiology studies\"\n    }\n  ],\n  \"monitoring_requirements\": [\n    \"Liver function tests (ALT/AST) at baseline and every 2-4 weeks for chronic use (>2 g/day or >7 days).\",\n    \"Serum paracetamol concentration 4 hours post-overdose using Rumack-Matthew nomogram.\",\n    \"INR and renal function in patients on warfarin or with CrCl <50 mL/min.\",\n    \"Signs/symptoms of hypersensitivity (rash, urticaria) with first doses.\"\n  ],\n  \"warning_signs\": [\n    {\n      \"Jaundice or dark urine\": \"Hepatotoxicity; discontinue immediately, measure LFTs, consider NAC.\"\n    },\n    {\n      \"Right upper quadrant pain or nausea/vomiting\": \"Early liver injury; urgent LFTs and paracetamol level.\"\n    },\n    {\n      \"Rash or mucosal involvement\": \"Hypersensitivity reaction; stop drug, supportive care.\"\n    }\n  ],\n  \"evidence_quality\": \"high\",\n  \"analysis_confidence\": 0.95\n}\n```",
    "token_usage": {
      "input_tokens": 1517,
      "output_tokens": 2659,
      "total_tokens": 6042
    }
  }
]